fenofibrate has been researched along with Hypertension in 56 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 9.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 9.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "Our objective was to determine whether fenofibrate modifies the metabolism of nonesterified (free) fatty acids as a component of its triglyceride-lowering action in male patients with the metabolic syndrome." | 9.10 | Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. ( Cater, NB; Grundy, SM; Hadizadeh, DR; Meguro, S; Vega, GL, 2003) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 9.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 7.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| "To investigate the effect of PPAR alpha activator fenofibrate on left ventricular hypertrophy and myocardium PPAR alpha (peroxisome proliferator-activated receptor-alpha) expression in spontaneously hypertensive rats (SHR)." | 7.74 | [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]. ( Chen, HJ; Chen, JZ; Wang, XX; Yu, M, 2007) |
| " The present study examined the effects of induction of the renal production of 20-HETE with fenofibrate (FF) on the development of angiotensin II (Ang II)-dependent hypertension in C57BL/6J mice." | 7.73 | Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. ( Bohman, Q; Flasch, A; Roman, RJ; Stec, DE; Taylor, M; Vera, T, 2005) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 7.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 5.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| "9%, respectively) and also for dyslipidemia (160 mg daily of fenofibrate plus simvastatin or placebo plus simvastatin) or for systolic blood-pressure control (target, <120 or <140 mm Hg)." | 5.14 | Effects of medical therapies on retinopathy progression in type 2 diabetes. ( Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U, 2010) |
| "The combination of antihypertensive agents with micronized fenofibrate can effectively prevent the progression of carotid atherosclerosis and reduce the incidence of stroke in patients with essential hypertension." | 5.12 | Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. ( Meng, QH; Su, G; Zhu, S, 2006) |
| "Improvement in lipid profiles with fenofibrate in patients with type 2 diabetes was associated with reduced progression from normal albumin excretion to microalbuminuria." | 5.11 | Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). ( Ansquer, JC; Foucher, C; Rattier, S; Steiner, G; Taskinen, MR, 2005) |
| "A combination of fenofibrate or losartan with anti-hyperuricaemic agents is a good option for the treatment of gout patients with hypertriglyceridaemia and/or hypertension, though the additional hypouricaemic effect may be modest." | 5.10 | Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. ( Fukuchi, M; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2003) |
| "Our objective was to determine whether fenofibrate modifies the metabolism of nonesterified (free) fatty acids as a component of its triglyceride-lowering action in male patients with the metabolic syndrome." | 5.10 | Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. ( Cater, NB; Grundy, SM; Hadizadeh, DR; Meguro, S; Vega, GL, 2003) |
| "These favourable effects of comicronised fenofibrate both on lipid and non lipid parameters, including insulin sensitivity, may confer to this product a particular interest in the treatment of patients with polymetabolic syndrome X." | 5.09 | Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X. ( Blane, G; Idzior-Walus, B; Kawalec, E; Rostworowski, W; Sieradzki, J; Wójcik, J; Zarnecki, A; Zdzienicka, A, 2000) |
| "Purpose - studying of clinical efficiensy of the combined therapy (Amlodipin with Valsartan and fibrates) in hypertensive patients with dyslipidemia." | 3.88 | [THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA]. ( Gegeshidze, N; Kapetivadze, V; Lazashvili, T; Maglapheridze, Z; Tabukashvili, R; Tchaava, K, 2018) |
| "We report on a 26-year-old male who presented with fenofibrate-induced rhabdomyolysis with chronic renal failure due to nephrotic syndrome." | 3.78 | Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report. ( Begenik, H; Canbaz, ET; Emre, H; Erdur, FM; Erkoc, R; Soyoral, YU, 2012) |
| " Patients were eligible for the analysis if they had a diagnosis of hypertension, dyslipidaemia or diabetes mellitus, were written a prescription for standard fenofibrate 160 mg during the period 1 May 2004 to 30 April 2005, and were written a subsequent prescription for fenofibrate 145 mg NFE at least 60 days after first receiving the 160 mg dose." | 3.74 | Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet. ( Davidson, MH; Jones, PH, 2008) |
| " We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM)." | 3.74 | Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. ( Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R, 2007) |
| "To investigate the effect of PPAR alpha activator fenofibrate on left ventricular hypertrophy and myocardium PPAR alpha (peroxisome proliferator-activated receptor-alpha) expression in spontaneously hypertensive rats (SHR)." | 3.74 | [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]. ( Chen, HJ; Chen, JZ; Wang, XX; Yu, M, 2007) |
| " The present study examined the effects of induction of the renal production of 20-HETE with fenofibrate (FF) on the development of angiotensin II (Ang II)-dependent hypertension in C57BL/6J mice." | 3.73 | Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice. ( Bohman, Q; Flasch, A; Roman, RJ; Stec, DE; Taylor, M; Vera, T, 2005) |
| "Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent." | 3.72 | Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. ( Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC, 2003) |
| "The PPAR alpha activator fenofibrate prevented development of hypertension, and improved myocardial inflammation and collagen deposition in Ang II-infused rats." | 3.72 | PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. ( Amiri, F; Benkirane, K; Cohn, JS; Diep, QN; Endemann, D; Schiffrin, EL, 2004) |
| "Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension in Dahl salt-sensitive (Dahl S) rats." | 3.70 | Effects of lipid-lowering agents in the Dahl salt-sensitive rat. ( Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998) |
| " It has been proposed that the elevated serum uric acid levels are linked to other risk factors, such as hypertension, dyslipidaemia and diabetes." | 3.70 | Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories. ( Elisaf, MS; Milionis, HJ, 2000) |
| "Patients with the metabolic syndrome are more likely to develop type 2 diabetes and may have an increased risk of cardiovascular disease (CVD) events." | 2.76 | Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. ( Colman, PG; Davis, TM; Donoghoe, M; Fulcher, G; Keech, AC; Manning, P; O'Brien, R; Pardy, C; Scott, R; Taskinen, MR; Watts, GF, 2011) |
| "Fenofibrate combined with candesartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy in hypertriglyceridemic hypertensive patients." | 2.72 | Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients. ( Ahn, JY; Chung, WJ; Han, SH; Kim, JA; Koh, KK; Lee, Y; Quon, MJ; Shin, EK, 2006) |
| "Hypertension and hyperlipidemia, which are also responsible for cardiovascular diseases, are often associated with hyperuricemia." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| "Metabolic syndrome is associated with increased cardiovascular risk." | 2.41 | [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome]. ( Idzior-Waluś, B, 2001) |
| "Fenofibrate has been used for decades against hypercholesterolemia and has no serious side effects." | 1.56 | Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19. ( Buschard, K, 2020) |
| "Hypertension is associated with endothelial dysfunction, which favors the release of endothelium-derived contracting factors, including vasoconstrictor prostanoids and reactive oxygen species." | 1.48 | PPAR-α agonists acutely inhibit Ca ( Chen, H; Leung, SWS; Man, RYK, 2018) |
| "Fenofibrate was used as the PPARα agonist." | 1.37 | Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart. ( Nair, RR; Purushothaman, S; Sathik, MM, 2011) |
| "Fenofibrate prevented the increase in BP in 4-5 week old SHRSP, reduced BP in 25 week old SHRSP, but had no effect on BP in normotensive SD rats." | 1.31 | Fenofibrate lowers blood pressure in two genetic models of hypertension. ( Quest, DW; Shatara, RK; Wilson, TW, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (3.57) | 18.2507 |
| 2000's | 31 (55.36) | 29.6817 |
| 2010's | 21 (37.50) | 24.3611 |
| 2020's | 2 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Willson, TM | 1 |
| Brown, PJ | 1 |
| Sternbach, DD | 1 |
| Henke, BR | 1 |
| Teoh, CS | 1 |
| Yuen, YS | 1 |
| Buschard, K | 1 |
| Skolnik, N | 1 |
| Jaffa, FM | 1 |
| Kalyani, RR | 1 |
| Johnson, E | 1 |
| Shubrook, JH | 1 |
| Chen, H | 1 |
| Man, RYK | 1 |
| Leung, SWS | 1 |
| Gremmels, H | 1 |
| Joles, JA | 1 |
| Tabukashvili, R | 1 |
| Kapetivadze, V | 1 |
| Tchaava, K | 1 |
| Gegeshidze, N | 1 |
| Lazashvili, T | 1 |
| Maglapheridze, Z | 1 |
| Zhu, Y | 2 |
| Wang, HS | 1 |
| Li, XM | 1 |
| Qu, C | 3 |
| Weng, H | 1 |
| Ji, X | 1 |
| Endo, K | 1 |
| Iwai, N | 1 |
| Ismael, S | 1 |
| Purushothaman, S | 2 |
| Harikrishnan, VS | 1 |
| Nair, RR | 2 |
| Koh, KK | 3 |
| Quon, MJ | 2 |
| Davidson, MH | 1 |
| Jones, PH | 1 |
| Lai, MY | 1 |
| Lin, CC | 1 |
| Chung, SL | 1 |
| Wu, CH | 1 |
| Yang, WC | 1 |
| Tseng, YT | 1 |
| Hou, X | 1 |
| Shen, YH | 1 |
| Li, C | 1 |
| Wang, F | 1 |
| Zhang, C | 1 |
| Bu, P | 1 |
| Zhang, Y | 1 |
| Nilsson, PM | 1 |
| Chew, EY | 1 |
| Ambrosius, WT | 1 |
| Davis, MD | 1 |
| Danis, RP | 1 |
| Gangaputra, S | 1 |
| Greven, CM | 1 |
| Hubbard, L | 1 |
| Esser, BA | 1 |
| Lovato, JF | 1 |
| Perdue, LH | 1 |
| Goff, DC | 1 |
| Cushman, WC | 1 |
| Ginsberg, HN | 1 |
| Elam, MB | 1 |
| Genuth, S | 1 |
| Gerstein, HC | 1 |
| Schubart, U | 1 |
| Fine, LJ | 1 |
| Ruiz, J | 1 |
| Egli, M | 1 |
| Gianinazzi, F | 1 |
| Izzo, F | 1 |
| Voeffray Favre, AC | 1 |
| Rossi, I | 1 |
| Bodenman, P | 1 |
| Gelosa, P | 1 |
| Banfi, C | 1 |
| Gianella, A | 1 |
| Brioschi, M | 1 |
| Pignieri, A | 1 |
| Nobili, E | 1 |
| Castiglioni, L | 1 |
| Cimino, M | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Liew, G | 1 |
| Wang, JJ | 1 |
| Mitchell, P | 1 |
| Siegel, D | 1 |
| Swislocki, AL | 1 |
| Sathik, MM | 1 |
| Erdur, FM | 1 |
| Soyoral, YU | 1 |
| Emre, H | 1 |
| Begenik, H | 1 |
| Canbaz, ET | 1 |
| Erkoc, R | 1 |
| Scott, R | 1 |
| Donoghoe, M | 1 |
| Watts, GF | 1 |
| O'Brien, R | 1 |
| Pardy, C | 1 |
| Taskinen, MR | 2 |
| Davis, TM | 1 |
| Colman, PG | 1 |
| Manning, P | 1 |
| Fulcher, G | 1 |
| Keech, AC | 1 |
| Rehman, HU | 1 |
| Tang, L | 1 |
| Leung, SW | 1 |
| Vanhoutte, PM | 1 |
| Man, RY | 1 |
| Iglarz, M | 2 |
| Touyz, RM | 2 |
| Amiri, F | 3 |
| Lavoie, MF | 1 |
| Diep, QN | 3 |
| Schiffrin, EL | 3 |
| Bardin, T | 1 |
| Takahashi, S | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 1 |
| Tsutsumi, Z | 1 |
| Ka, T | 1 |
| Fukuchi, M | 1 |
| Viel, EC | 1 |
| Paradis, P | 1 |
| Vega, GL | 1 |
| Cater, NB | 1 |
| Hadizadeh, DR | 1 |
| Meguro, S | 1 |
| Grundy, SM | 1 |
| Muller, DN | 1 |
| Theuer, J | 1 |
| Shagdarsuren, E | 1 |
| Kaergel, E | 1 |
| Honeck, H | 1 |
| Park, JK | 1 |
| Markovic, M | 1 |
| Barbosa-Sicard, E | 1 |
| Dechend, R | 1 |
| Wellner, M | 1 |
| Kirsch, T | 1 |
| Fiebeler, A | 1 |
| Rothe, M | 1 |
| Haller, H | 1 |
| Luft, FC | 1 |
| Schunck, WH | 1 |
| Benkirane, K | 1 |
| Cohn, JS | 1 |
| Endemann, D | 1 |
| Ogata, T | 1 |
| Miyauchi, T | 1 |
| Sakai, S | 1 |
| Takanashi, M | 1 |
| Irukayama-Tomobe, Y | 1 |
| Yamaguchi, I | 1 |
| Vera, T | 1 |
| Taylor, M | 1 |
| Bohman, Q | 1 |
| Flasch, A | 1 |
| Roman, RJ | 2 |
| Stec, DE | 1 |
| Ansquer, JC | 1 |
| Foucher, C | 1 |
| Rattier, S | 1 |
| Steiner, G | 1 |
| Coban, E | 1 |
| Ozdogan, M | 1 |
| Yazicioglu, G | 1 |
| Sari, R | 1 |
| Erol, A | 1 |
| Han, SH | 1 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Kim, JA | 1 |
| Lee, Y | 1 |
| Shin, EK | 1 |
| Ichihara, S | 1 |
| Obata, K | 1 |
| Yamada, Y | 1 |
| Nagata, K | 1 |
| Noda, A | 1 |
| Ichihara, G | 1 |
| Yamada, A | 1 |
| Kato, T | 1 |
| Izawa, H | 1 |
| Murohara, T | 1 |
| Yokota, M | 1 |
| Zhu, S | 1 |
| Su, G | 1 |
| Meng, QH | 1 |
| Duhaney, TA | 2 |
| Cui, L | 2 |
| Rude, MK | 1 |
| Lebrasseur, NK | 2 |
| Ngoy, S | 1 |
| De Silva, DS | 2 |
| Siwik, DA | 1 |
| Liao, R | 1 |
| Sam, F | 2 |
| Ip, PC | 1 |
| Joseph, L | 1 |
| Yagil, C | 1 |
| Yagil, Y | 1 |
| Tordjman, KM | 1 |
| Semenkovich, CF | 1 |
| Coleman, T | 1 |
| Yudovich, R | 1 |
| Bak, S | 1 |
| Osher, E | 1 |
| Vechoropoulos, M | 1 |
| Stern, N | 1 |
| Chen, HJ | 1 |
| Chen, JZ | 1 |
| Wang, XX | 1 |
| Yu, M | 1 |
| Carlson, JA | 1 |
| Mazza, J | 1 |
| Kircher, K | 1 |
| Tran, TA | 1 |
| Ogino, K | 1 |
| Igawa, O | 1 |
| Hisatome, I | 1 |
| Wilson, TW | 2 |
| Alonso-Galicia, M | 1 |
| Elisaf, M | 2 |
| Tsimichodimos, V | 1 |
| Bairaktari, E | 2 |
| Siamopoulos, KC | 1 |
| Shatara, RK | 1 |
| Quest, DW | 1 |
| Idzior-Walus, B | 2 |
| Sieradzki, J | 1 |
| Rostworowski, W | 1 |
| Zdzienicka, A | 1 |
| Kawalec, E | 1 |
| Wójcik, J | 1 |
| Zarnecki, A | 1 |
| Blane, G | 1 |
| Milionis, HJ | 1 |
| Elisaf, MS | 1 |
| Achimastos, A | 1 |
| Liberopoulos, E | 1 |
| Nikas, S | 1 |
| Miltiadous, G | 1 |
| Tsimihodimos, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Action to Control Cardiovascular Risk in Diabetes (ACCORD)[NCT00000620] | Phase 3 | 10,251 participants (Actual) | Interventional | 1999-09-30 | Completed | ||
| Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study[NCT00542178] | Phase 3 | 3,472 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy[NCT03869931] | Phase 3 | 300 participants (Anticipated) | Interventional | 2019-03-08 | Recruiting | ||
| Effects of Fenofibrate on Metabolic and Reproductive Parameters in Polycystic Ovary Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial[NCT00884819] | 4 participants (Actual) | Interventional | 2008-12-31 | Terminated (stopped due to Poor recruitment) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Time to death from any cause. Secondary measure for Glycemia Trial.~A finding of higher mortality in the intensive-therapy group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid)." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 391 |
| Glycemia Trial: Standard Control | 327 |
"Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. This was the primary outcome measure in all three trials: Glycemia (all participants), Blood Pressure (subgroup of participants not in Lipid Trial), and Lipid (subgroup of participants not in Blood Pressure Trial).~In the Glycemia Trial, a finding of higher mortality in the intensive arm group led to an early discontinuation of therapy after a mean of 3.5 years of follow-up. Intensive arm participants were transitioned to standard arm strategy over a period of 0.2 year and followed for an additional 1.2 years to the planned end of the Glycemia Trial while participating in one of the other sub-trials (BP or Lipid) to their planned completion." (NCT00000620)
Timeframe: 4.9 years
| Intervention | participants (Number) |
|---|---|
| Glycemia Trial: Intensive Control | 503 |
| Glycemia Trial: Standard Control | 543 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. Primary outcome for Blood Pressure Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 208 |
| BP Trial: Standard Control | 237 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 291 |
| Lipid Trial: Placebo | 310 |
Time to first occurrence of nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, revascularization procedure or hospitalization for CHF in Lipid Trial participants. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| Lipid Trial: Fenofibrate | 641 |
| Lipid Trial: Placebo | 667 |
Time to first occurrence of nonfatal or fatal stroke among participants in the BP Trial. (NCT00000620)
Timeframe: 4.7 years
| Intervention | participants (Number) |
|---|---|
| BP Trial: Intensive Control | 36 |
| BP Trial: Standard Control | 62 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 547 |
| Standard Glycemia Control | 623 |
| Intensive Blood Pressure Control | 266 |
| Standard Blood Pressure Control | 300 |
| Fenofibrate + Simvastatin Therapy | 305 |
| Placebo + Simvastatin Therapy | 299 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 44 |
| Standard Glycemia Control | 40 |
| Intensive Blood Pressure Control | 18 |
| Standard Blood Pressure Control | 20 |
| Fenofibrate + Simvastatin Therapy | 24 |
| Placebo + Simvastatin Therapy | 22 |
(NCT00542178)
Timeframe: Measured at Year 4
| Intervention | Participants (Count of Participants) |
|---|---|
| Intensive Glycemia Control | 744 |
| Standard Glycemia Control | 752 |
| Intensive Blood Pressure Control | 367 |
| Standard Blood Pressure Control | 382 |
| Fenofibrate + Simvastatin Therapy | 354 |
| Placebo + Simvastatin Therapy | 393 |
Diabetic retinopathy status was defined according to the eye with the highest level on the ETDRS Final Severity Scale for Persons, as follows: no diabetic retinopathy, a level of less than 20; mild diabetic retinopathy, a level of 20; moderate nonproliferative diabetic retinopathy (NPDR), a level above 20 but less than 53; severe diabetic retinopathy, a level of 53 but less than 60; and proliferative diabetic retinopathy (PDR), a level of 60 or higher. (NCT00542178)
Timeframe: Measured at Year 4
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemia Control | 104 |
| Standard Glycemia Control | 149 |
| Intensive Blood Pressure Control | 67 |
| Standard Blood Pressure Control | 54 |
| Fenofibrate + Simvastatin Therapy | 52 |
| Placebo + Simvastatin Therapy | 80 |
3 reviews available for fenofibrate and Hypertension
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligand | 2000 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
[Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].
Topics: Cardiovascular Diseases; Clofibrate; Fenofibrate; Hemostasis; Humans; Hyperinsulinism; Hyperlipidemi | 2001 |
9 trials available for fenofibrate and Hypertension
| Article | Year |
|---|---|
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabe | 2010 |
The ACCORD Study: the devil is in the details.
Topics: Blood Pressure; Cardiovascular Diseases; Data Interpretation, Statistical; Diabetes Mellitus, Type 2 | 2011 |
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Topics: Aged; Australia; Cardiovascular Diseases; Cholesterol, HDL; Cohort Studies; Diabetes Mellitus, Type | 2011 |
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
Topics: Adult; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Fenofibrate; Gout Suppressants; | 2003 |
Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Topics: Adipose Tissue; Cholesterol; Cholesterol, HDL; Cholesterol, VLDL; Fatty Acids, Nonesterified; Fenofi | 2003 |
Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2005 |
Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; Biphe | 2006 |
Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Biomarkers; Carotid Artery Diseases; Demography; | 2006 |
Effects of comicronised fenofibrate on lipid and insulin sensitivity in patients with polymetabolic syndrome X.
Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Blood Glucose; Blood | 2000 |
44 other studies available for fenofibrate and Hypertension
| Article | Year |
|---|---|
Spectral-Domain OCT Imaging of Lipemia Retinalis.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol; Diabetes Complications; Drug Therapy, Combinati | 2021 |
Fenofibrate increases the amount of sulfatide which seems beneficial against Covid-19.
Topics: Adult; Aging; Betacoronavirus; Child; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dru | 2020 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; | 2017 |
PPAR-α agonists acutely inhibit Ca
Topics: Animals; Antihypertensive Agents; Antioxidants; Aorta; Disease Models, Animal; Fenofibrate; Hydrogen | 2018 |
Fibrates in hypertension: where do we stand?
Topics: Animals; Fenofibrate; Fibric Acids; Hypertension; Rats; Rats, Inbred SHR; Stroke | 2018 |
[THE COMBINED THERAPY IN HYPERTENSIVE PATIENTS WITH DYSLIPIDEMIA].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Combinations; Drug Therapy, Combination; Dysl | 2018 |
Effects and mechanisms of Fenofibrate on the secretion of vascular endothelial contraction factors in hypertensive rats.
Topics: Anilides; Animals; Aorta; Cyclooxygenase 1; Dinoprost; Dose-Response Relationship, Drug; Endothelium | 2014 |
Pex11a deficiency is associated with a reduced abundance of functional peroxisomes and aggravated renal interstitial lesions.
Topics: Animals; Disease Models, Animal; Fatty Acids; Female; Fenofibrate; Fibrosis; Hypertension; Hypolipid | 2014 |
Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat.
Topics: Acyl-CoA Dehydrogenase; Animals; Blood Pressure; Cardiomegaly; Fenofibrate; Gene Expression; Hyperte | 2015 |
Combination therapy for treatment or prevention of atherosclerosis.
Topics: Atherosclerosis; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Drug Therapy, Combin | 2008 |
Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Dose-Response Relationship | 2008 |
Milky plasma, diabetes, and severe hyponatremia.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypertension; Hyponat | 2009 |
PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity.
Topics: Animals; Antioxidants; Collagen; Fenofibrate; Hypertension; Kidney Diseases; Male; MAP Kinase Kinase | 2010 |
ACCORD and Risk-Factor Control in Type 2 Diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combinati | 2010 |
[Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Hu | 2010 |
Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.
Topics: Animals; Blotting, Western; Brain; Chemokine CCL2; Clofibrate; Disease Models, Animal; Fenofibrate; | 2010 |
Retinopathy progression in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Fenofibrate; Humans; Hypertens | 2010 |
Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.
Topics: Aging; Animals; Azo Compounds; Blood Pressure; Body Weight; Cholesterol; Disease Models, Animal; Ene | 2011 |
Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.
Topics: Adult; Fatigue; Fenofibrate; Humans; Hypertension; Hypoalbuminemia; Hypolipidemic Agents; Kidney Fai | 2012 |
The work-up for mixed hyperlipidemia: a case study.
Topics: Adult; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Electrophoresis; Fenofibrate; Fluor | 2012 |
Effect of fenofibrate on the secretion of endothelium-derived contracting factors in hypertensive rats.
Topics: Animals; Cyclooxygenase 1; Epoprostenol; Fenofibrate; Hypertension; Male; Membrane Proteins; Rats; R | 2012 |
Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha.
Topics: Animals; Aorta, Thoracic; Fenofibrate; Hypertension; In Vitro Techniques; Male; Peroxisome Prolifera | 2012 |
Does fenofibrate lower blood pressure?
Topics: Antihypertensive Agents; Blood Pressure; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase In | 2013 |
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; | 2003 |
Fenofibrate and losartan.
Topics: Drug Therapy, Combination; Fenofibrate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Losa | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; En | 2003 |
A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.
Topics: 8,11,14-Eicosatrienoic Acid; Angiotensin II; Angiotensinogen; Animals; Animals, Genetically Modified | 2004 |
PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.
Topics: Angiotensin II; Animals; Blood Pressure; Collagen; Electrocardiography; Fenofibrate; Fibrosis; Heart | 2004 |
Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with
Topics: Animals; Blotting, Western; Cardiac Output, Low; Desoxycorticosterone; Diastole; Fenofibrate; Fibros | 2004 |
Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice.
Topics: Angiotensin II; Animals; Blood Pressure; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Fen | 2005 |
The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients.
Topics: Adult; Anti-Inflammatory Agents; Body Mass Index; C-Reactive Protein; Fenofibrate; Humans; Hyperlipi | 2005 |
PPARalpha activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients.
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Fenofibrate; Humans; Hyperlipidemias; Hypertensio | 2006 |
Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.
Topics: Animals; Cytokines; Down-Regulation; Fenofibrate; Glucose; Heart Ventricles; Hypertension; Hypertrop | 2006 |
Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.
Topics: Aldosterone; Animals; Cells, Cultured; Chronic Disease; Extracellular Signal-Regulated MAP Kinases; | 2007 |
Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.
Topics: Aldosterone; Animals; Blood Pressure; Extracellular Matrix; Fenofibrate; Fibrosis; Heart; Heart Rate | 2007 |
Peroxisome proliferator-activated receptor alpha: friend or foe?
Topics: Animals; Atherosclerosis; Blood Pressure; Docosahexaenoic Acids; Fenofibrate; Humans; Hypertension; | 2007 |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogen | 2007 |
[PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats].
Topics: Animals; Blood Pressure; Blotting, Western; Fenofibrate; Hypertension; Hypertrophy, Left Ventricular | 2007 |
Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.
Topics: Adrenal Cortex Hormones; Alcoholism; Anti-Infective Agents; Anti-Inflammatory Agents; Antidepressive | 2008 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sy | 1998 |
Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Blood Chemical Analysis; Female; Fenofibrate; Humans; Hyperten | 1999 |
Fenofibrate lowers blood pressure in two genetic models of hypertension.
Topics: Animals; Blood Glucose; Blood Pressure; Fenofibrate; Hypertension; Hypolipidemic Agents; Male; Prote | 2000 |
Management of hypertension and dyslipidaemia in patients presenting with hyperuricaemia: case histories.
Topics: Antihypertensive Agents; Arteriosclerosis; Benzothiadiazines; Diuretics; Female; Fenofibrate; Humans | 2000 |
The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.
Topics: Adult; Aged; Antihypertensive Agents; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Drug Therapy | 2002 |